Trial · NCT00402896
Malignant Pleural Effusion With ZD6474
NCT00402896, Phase 2, Terminated, M.D. Anderson Cancer Center; results first posted 2016-03-09
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Malignant Pleural Effusion With ZD6474. Trials, record NCT00402896. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00402896
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Malignant Pleural Effusion With ZD6474
- NCT number
- NCT00402896
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 28 participants, actual
- Lead sponsor
- M.D. Anderson Cancer Center
- Conditions
- Lung Cancer, Pleural Effusion
- Interventions
- ZD6474
- First posted
- 2006-11-22
- Last updated
- 2016-03-09
- Results first posted
- 2016-03-09
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Median Time to Pleurodesis | Time from initiation of treatment and catheter insertion up to a maximum of 10 weeks | Time to pleurodesis from initiation of treatment to catheter removal as measure of pleural effusion Improvement (amount of pleural fluid drainage) where objective was to examine whether ZD6474 would help participants to improve the condition of pleural effusion, and thus remove the catheter earlier. Cox model analysis applied to examine the effect of covariates on the time to catheter removal. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Median Time to Pleurodesis | Time from initiation of treatment and catheter insertion up to a maximum of 10 weeks | Twenty eligible participants were analyzed for the primary outcome in the trial, eleven completed 10 weeks of treatment. All twenty participants completed the study. | Days | MEDIAN |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Median Time to Pleurodesis | ZD6474 | 35 | 95% Confidence Interval 15 to NA | Days |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | ZD6474 | 20 | |
| Overall Study | COMPLETED | ZD6474 | 20 | |
| Overall Study | NOT COMPLETED | ZD6474 | 0 |
Source ClinicalTrials.gov
Adverse events50
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anemia | Blood and lymphatic system disorders | ZD6474 | 1 | 20 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | ZD6474 | 2 | 20 | |
| other | Prolonged PTT | Blood and lymphatic system disorders | ZD6474 | 1 | 20 | |
| other | Fatigue | General disorders | ZD6474 | 7 | 20 | |
| other | Weight loss | General disorders | ZD6474 | 5 | 20 | |
| other | Anorexia | Gastrointestinal disorders | ZD6474 | 2 | 20 | |
| other | Nausea | Gastrointestinal disorders | ZD6474 | 3 | 20 | |
| other | Vomiting | Gastrointestinal disorders | ZD6474 | 1 | 20 | |
| other | Diarrhea | Gastrointestinal disorders | ZD6474 | 12 | 20 | |
| other | Constipation | Gastrointestinal disorders | ZD6474 | 1 | 20 |
1 to 10 of 50Source ClinicalTrials.gov
See all 50 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | ZD6474 | ||
| Total, other adverse events | ZD6474 | 20 | 20 |
| Total, serious adverse events | ZD6474 | 12 | 20 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 24913066 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00402896
GET https://conductscience.org/api/trials/v1/NCT00402896/events?page=2